SAM
TVTX icon

Senzar Asset Management’s Travere Therapeutics TVTX Stock Holding History

Senzar Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-246,289
Closed -$4.78M – 35
2017
Q2 		$4.78M Sell
246,289
-183,900
-43% -$3.34M 1.18% 20
2017
Q1 		$7.94M Sell
430,189
-62,700
-13% -$1.23M 2.01% 18
2016
Q4 		$9.33M Buy
492,889
+22,100
+5% +$452K 2.47% 11
2016
Q3 		$10.5M Buy
470,789
+141,300
+43% +$2.69M 2.72% 13
2016
Q2 		$5.87M Sell
329,489
-785,103
-70% -$12.7M 1.28% 24
2016
Q1 		$15.2M Buy
1,114,592
+55,710
+5% +$845K 3.02% 10
2015
Q4 		$20.4M Buy
1,058,882
+336,782
+47% +$6.73M 2.27% 14
2015
Q3 		$14.6M Buy
722,100
+512,600
+245% +$15.2M 2.13% 14
2015
Q2 		$6.95M Sell
209,500
-269,400
-56% -$7.38M 1.19% 30
2015
Q1 		$11.5M Sell
478,900
-156,800
-25% -$2.39M 2.8% 12
2014
Q4 		$7.78M Buy
635,700
+343,300
+117% +$3.55M 2.28% 21
2014
Q3 		$2.64M Buy
292,400
+134,300
+85% +$1.58M 0.77% 27
2014
Q2 		$1.86M Buy
+158,100
New +$2.14M 0.71% 26

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Senzar Asset Management's TVTX Position: Q3 2017 in Review

Senzar Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2017, closing a stake of 246,289 shares — an estimated $4.78M sold.

Senzar Asset Management first reported a position in TVTX in Q2 2014 and held it in 13 quarters. The position peaked at $20.4M in Q4 2015. 113 funds tracked by Wall St. Rank hold TVTX as of Q3 2017.

  • Senzar Asset Management reported no remaining Travere Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Senzar Asset Management sold 246,289 Travere Therapeutics shares in Q3 2017, an estimated $4.78M.
  • Senzar Asset Management first reported a position in Travere Therapeutics in Q2 2014 and held it in 13 quarters.
  • Senzar Asset Management's Travere Therapeutics position peaked at $20.4M in Q4 2015.
  • 113 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2017.

Based on Senzar Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.